Patients with polymyalgia rheumatica were more likely to discontinue steroids after treatment with sarilumab compared to methotrexate, according to data presented at ACR Convergence 2024. A study analyzed commercial claims data from Komodo HealthMap and found that 59% of patients using sarilumab were able to discontinue glucocorticoids within 6 months, compared to 35% for methotrexate. Patients on sarilumab required fewer days on steroids and a lower cumulative dose compared to methotrexate. This study provides evidence that sarilumab is an effective steroid-sparing agent for patients with polymyalgia rheumatica, offering rheumatologists a new treatment option to consider.
Source link
Health Information Management